Nabriva Therapeutics plc
NBRV
주식 순위
#39899
Nabriva Therapeutics plc is a biopharmaceutical company focused on the... Nabriva Therapeutics plc is a biopharmaceutical company focused on the discovery and commercialization of innovative anti-infective medications to combat serious infections. The company's current marketed products include SIVEXTRO, an oxazolidinone-class antibacterial designed for the treatment of acute bacterial skin and skin structure infections (ABSSSI), and XENLETA, a semi-synthetic pleuromutilin antibiotic utilized in managing community-acquired bacterial pneumonia. Beyond its existing offerings, Nabriva is further exploring XENLETA's potential in Phase I clinical trials for a broad spectrum of indications, such as pediatric infections, sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated and hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. Additionally, the firm is developing CONTEPO, an epoxide antibiotic for complicated urinary tract infections, which is also undergoing Phase I clinical evaluation for peri-operative prophylaxis. Originally incorporated in 2005 as Nabriva Therapeutics Forschungs GmbH, the company rebranded to Nabriva Therapeutics plc in 2007 and maintains its corporate headquarters in Dublin, Ireland.
주가
$0.63
마지막 동기화: 2023-08-29
시가총액
$284.20K
변동 (1일)
-21.25%
변동 (1년)
629,900.02%
국가
IE
거래 Nabriva Therapeutics plc (NBRV)
카테고리
Healthcare
의 시가총액 Nabriva Therapeutics plc(NBRV)
시가총액: $284.20K
October 2026 기준으로 Nabriva Therapeutics plc의 시가총액은 $284.20K입니다. 이는 당사 데이터에 따르면 Nabriva Therapeutics plc이 세계에서 39899th번째로 가치 있는 기업임을 의미합니다. 시가총액은 상장된 회사의 발행 주식 총 시장 가치를 의미하며, 일반적으로 회사의 가치를 측정하는 데 사용됩니다.
2023부터 2026까지 Nabriva Therapeutics plc의 시가총액 기록
NBRV 가장 인기있는 상위 5 가지 stocks과 비교하여
